Centene (CNC) Gets a Hold from Cantor Fitzgerald

In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Hold rating on Centene, with a price target of $41.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

James covers the Healthcare sector, focusing on stocks such as Molina Healthcare, HCA Healthcare, and CVS Health. According to TipRanks, James has an average return of 4.1% and a 53.47% success rate on recommended stocks.

In addition to Cantor Fitzgerald, Centene also received a Hold from TipRanks – OpenAI’s OpenAI Medical – Healthcare Plans in a report issued on February 7. However, today, Truist Financial reiterated a Buy rating on Centene (NYSE: CNC).

Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.73 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $40.81 billion and had a net profit of $283 million

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNC in relation to earlier this year. Most recently, in December 2025, Kenneth Burdick, a Director at CNC sold 66,007.00 shares for a total of $2,575,601.44.